Harmony Biosciences is trading 6.37% down at $31.00 in pre-market after its November 4 earnings report showed diluted EPS of $0.81 below estimates.
- WAKIX revenue grew 12% year over year; full-year guidance was reaffirmed.
- Increased royalties and milestone charges weighed on profitability; cost of product sold rose to 30% of revenue from 25% a year earlier.
- Post-report volatility continues; no company-specific announcement surfaced for November 9. Indices were higher; pre-market volume was not provided.